Stay updated with breaking news from Query Get. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.Similar treatment-related toxicities occurred regardless of patients’ race or ethnicity, findings published in Bone Marrow Transplantation showed.
The FDA declined a request to authorize an inexpensive generic antidepressant and obsessive-compulsive disorder medication for emergency use as an outpatient treatment for COVID-19.
Travere Therapeutics Inc. announced the FDA has accepted and granted priority review of its new drug application under subpart H for accelerated approval of sparsentan for treatment of IgA nephropathy.According to the company press release, sparsentan is a dual endothelin angiotensin receptor antagonist that targets the endothelin A receptor and the angiotensin II subtype 1 receptor.
FORT LAUDERDALE, Fla. — Susvimo was noninferior to monthly ranibizumab and provided comparable vision and controlled retinal thickness through 96 weeks, according to data from the Archway trial.At the Retina World Congress, Aleksandra Rachitskaya, MD, presented end-of-study results from the phase 3 trial, which explored the safety and efficacy of Susvimo (ranibizumab injection, Genentech)
Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with unresctable or metastatic urothelial carcinoma whose tumor cells expressed PD-L1 at 1% or greater.An independent data monitoring committee recommended the randomized phase 3 CheckMate -901 trial continue to allow for assessment of other primary and secondary endpoints.